 |
17 Diseases |  |
3 Trials |
|
3 Trials |  |
24 News |  |
- | Foradil Aerolizer (formoterol dry powder inhaler) / Novartis
Trial withdrawal: Effect of Gly16Arg Polymorphism in ADRB2 Gene on Asthma Control in Children Receiving Long Acting Beta Agonists (clinicaltrials.gov) - May 26, 2023
P4, N=0, Withdrawn, Sponsor: Nemours Children's Clinic
Terminated --> Withdrawn
- | Formoterol Clickhaler (formoterol dry-powder inhaler) / Vectura, Foradil Aerolizer (formoterol dry powder inhaler) / Novartis, budesonide / Generic mfg.
Journal: Variability in airway inflammation, symptoms, lung function and reliever use in asthma: anti-inflammatory reliever hypothesis and STIFLE study design. (Pubmed Central) - Jun 19, 2020
Daily data will be captured for fractional exhaled nitric oxide, spirometry, asthma symptoms and medication use using devices connected to a smartphone via the STIFLE application. STIFLE will thereby enable not only characterisation of the variability of airway inflammation and clinical outcomes in relation to asthma worsening, but also elucidate the effect of as-needed budesonide/formoterol on airway inflammation against a background of daily maintenance therapy.
- Breztri Aerosphere (budesonide/formoterol fumarate/glycopyrronium) / AstraZeneca, Bevespi Aerosphere (glycopyrrolate and formoterol) / AstraZeneca
Estimated lifetime effectiveness of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) versus dual LAMA/LABA and ICS/LABA therapies in moderate-to-very severe COPD (TP-12) - Aug 26, 2019 - Abstract #ERS2019ERS_2631;
P3
Objective: To estimate the lifetime clinical effectiveness of BGF MDI versus LAMA/LABA (glycopyrrolate/formoterol fumarate MDI) and ICS/LABA (budesonide/formoterol dry powder inhaler) therapies in patients with moderate-to-very severe COPD. Modelling using KRONOS data demonstrated better outcomes with BGF MDI versus dual therapies over a lifetime, particularly in reducing exacerbations, for patients with COPD.
- | Bevespi Aerosphere (glycopyrrolate and formoterol) / AstraZeneca, Avelox (moxifloxacin) / Bayer
Clinical, Journal: Cardiovascular safety profile of a fixed-dose combination of glycopyrrolate and formoterol fumarate delivered via metered dose inhaler using co-suspension delivery technology. (Pubmed Central) - Apr 26, 2019
P2
No clinically significant effects on cardiovascular safety occurred at therapeutic or supratherapeutic doses of GFF MDI, apart from a small and transient increase in heart rate following supratherapeutic dose of GFF MDI 144/38.4 μg. Furthermore, there were no unexpected safety findings reported in either healthy volunteers or patients with COPD.
- | Symbicort (budesonide) / AstraZeneca, Foradil Aerolizer (formoterol dry powder inhaler) / Novartis
Clinical, Journal: Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study. (Pubmed Central) - Apr 24, 2019
P=N/A, P4
An exploratory independent expert-verified analysis found Spiromax was associated with higher levels of device mastery after 12 weeks. Asthma control was improved by treatment with both BF Spiromax and BF Turbuhaler.
- Duaklir (aclidinium bromide/formoterol fumarate) / Covis Pharma
Phase classification: Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Jun 17, 2016
P2a, N=24, Completed, Sponsor: AstraZeneca
Asthma control was improved by treatment with both BF Spiromax and BF Turbuhaler. Phase classification: P2 --> P2a
- formoterol fumarate (PT005) / AstraZeneca
Enrollment change: Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control (clinicaltrials.gov) - Jul 12, 2014
P2b, N=0, Withdrawn, Sponsor: Pearl Therapeutics, Inc.
Phase classification: P2 --> P2a N=60 --> 0
- |||| Tudorza (aclidinium bromide) / Almirall, Covis Pharma, Foradil Aerolizer (formoterol dry powder inhaler) / Novartis, formoterol fumarate (PT005) / AstraZeneca
Trial completion: Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma (clinicaltrials.gov) - Feb 12, 2013
P2, N=174, Completed, Sponsor: Forest Laboratories
N=60 --> 0 Active, not recruiting --> Completed
- | Duaklir (aclidinium bromide/formoterol fumarate) / Covis Pharma
Trial completion: Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Aug 21, 2012
P2, N=24, Completed, Sponsor: Forest Laboratories
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Tudorza (aclidinium bromide) / Almirall, Covis Pharma, Foradil Aerolizer (formoterol dry powder inhaler) / Novartis, formoterol fumarate (PT005) / AstraZeneca
New P2 trial: Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma (clinicaltrials.gov) - Jul 12, 2012
P2, N=174, Completed, Sponsor: Forest Laboratories
- Foradil Aerolizer (formoterol dry powder inhaler) / Novartis
Trial termination: Effect of Gly16Arg Polymorphism in ADRB2 Gene on Asthma Control in Children Receiving Long Acting Beta Agonists (clinicaltrials.gov) - May 1, 2012
P4, N=4, Terminated, Sponsor: Nemours Children's Clinic
Active, not recruiting --> Completed Not yet recruiting --> Terminated
- Foradil Aerolizer (formoterol dry powder inhaler) / Novartis
Enrollment change: Effect of Gly16Arg Polymorphism in ADRB2 Gene on Asthma Control in Children Receiving Long Acting Beta Agonists (clinicaltrials.gov) - May 1, 2012
P4, N=4, Terminated, Sponsor: Nemours Children's Clinic
Not yet recruiting --> Terminated N=90 --> 4
- | Duaklir (aclidinium bromide/formoterol fumarate) / Covis Pharma
New P2 trial: Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (clinicaltrials.gov) - Mar 11, 2012
P2, N=24, Completed, Sponsor: Forest Laboratories
- |||| budesonide/formoterol / Generic mfg.
Trial completion: CHASE 2: A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy (clinicaltrials.gov) - Feb 6, 2012
P2, N=54, Completed, Sponsor: AstraZeneca
N=90 --> 4 Recruiting --> Completed
- |||| Trial completion: PT003 MDI Cardiovascular Safety Study (clinicaltrials.gov) - Dec 5, 2011
P2, N=237, Completed, Sponsor: Pearl Therapeutics, Inc.
Recruiting --> Completed Recruiting --> Completed
- |||| Foradil Aerolizer (formoterol dry powder inhaler) / Novartis
Trial completion, Combination therapy: A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2) (clinicaltrials.gov) - Nov 20, 2011
P2, N=92, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Recruiting --> Completed
- | formoterol fumarate (PT005) / AstraZeneca
Trial completion: PT005 MDI Dose Ranging Versus Foradil Aerolizer Study (clinicaltrials.gov) - Aug 15, 2011
P2, N=50, Completed, Sponsor: Pearl Therapeutics, Inc.
Recruiting --> Completed Active, not recruiting --> Completed